In 2025 Pfizer released topline data from its VESPER-3 trial showing that its once-monthly GLP-1 candidate, Metsera, achieved average weight loss of 14.8% over 24 weeks, closely matching the 15.2% and 15.5% reductions reported by leading rivals in their Phase II programs. Building on that success, the company plans to initiate more than 20 pivotal obesity therapy studies in 2026, including head-to-head comparisons against established therapies and combination regimens targeting both appetite regulation and metabolic control. This aggressive clinical schedule is designed to differentiate Metsera’s monthly dosing advantage and support potential label expansions into related cardiometabolic indications by 2028.

Pfizer’s fourth-quarter and full-year 2025 results showed company-wide revenue growth of 6% excluding one-time COVID product sales, driven by a 9% year-over-year rise in oncology portfolio revenues and a 7% increase in hospital vaccine sales. Non-cash impairments related to legacy programs contributed to the 5% stock pullback in pre-market trading, but management emphasized that core operating profit margins expanded by 120 basis points, reflecting improved manufacturing efficiencies and disciplined R&D spending. Conservative 2026 guidance assumes mid-single-digit growth, but the underlying business—excluding pandemic downturn—delivered its highest annual margin gain since 2018.

With over 100 candidates in development, Pfizer expects to read out more than 20 Phase III trial results next year across oncology, neurology and metabolic diseases. Key programs include a BRAF/MEK inhibitor in third-line melanoma, an oral CGRP antagonist for chronic migraine prevention, and an IL-5 monoclonal antibody for severe eosinophilic asthma. Each program has peak sales potential in excess of $2 billion, according to internal forecasts. Successful launches could offset looming patent expirations—Xeljanz in mid-2026 and Eliquis in 2028—mitigating revenue erosion and sustaining long-term growth.

Trading at approximately 9x projected 2026 earnings versus a 22x average for the broader index, Pfizer offers a 6.6% annual dividend yield that ranks in the top decile of large-cap pharmaceuticals. Elevated market volatility and historically high valuation multiples in growth sectors create an opportunity for defensive, income-generating names with strong pipelines. Pfizer’s diversified revenue streams, commitment to returning excess cash through dividends and share buybacks, and the potential of its obesity franchise to capture substantial market share underpin its resilience and upside should broader equity markets face correctionary pressures.